![]() |
Name |
Tetrahydrobisvertinolone
|
Molecular Formula | C28H36O9 | |
IUPAC Name* |
(4S,4aR,5aS,9aR,9bR)-2,9-bis[(E)-hex-4-enoyl]-1,4,4a,6,8-pentahydroxy-4,5a,7,9b-tetramethyl-9aH-dibenzofuran-3-one
|
|
SMILES |
C/C=C/CCC(=O)C1=C(C(=C([C@@]2([C@H]1[C@@]3(C(=C(C(=O)[C@]([C@@]3(O2)O)(C)O)C(=O)CC/C=C/C)O)C)C)O)C)O
|
|
InChI |
InChI=1S/C28H36O9/c1-7-9-11-13-16(29)18-20(31)15(3)22(32)26(5)21(18)25(4)23(33)19(17(30)14-12-10-8-2)24(34)27(6,35)28(25,36)37-26/h7-10,21,31-33,35-36H,11-14H2,1-6H3/b9-7+,10-8+/t21-,25-,26+,27+,28-/m1/s1
|
|
InChIKey |
FEQQKMZNFKCWST-QCNVSJCTSA-N
|
|
Synonyms |
Tetrahydrobisvertinolone
|
|
CAS | NA | |
PubChem CID | 11272310 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 516.6 | ALogp: | 1.9 |
HBD: | 5 | HBA: | 9 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 162.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 37 | QED Weighted: | 0.232 |
Caco-2 Permeability: | -5.403 | MDCK Permeability: | 0.00005610 |
Pgp-inhibitor: | 0.457 | Pgp-substrate: | 0.957 |
Human Intestinal Absorption (HIA): | 0.037 | 20% Bioavailability (F20%): | 0.592 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.028 | Plasma Protein Binding (PPB): | 76.87% |
Volume Distribution (VD): | 0.749 | Fu: | 9.79% |
CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.678 |
CYP2C19-inhibitor: | 0.013 | CYP2C19-substrate: | 0.729 |
CYP2C9-inhibitor: | 0.005 | CYP2C9-substrate: | 0.017 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.03 |
CYP3A4-inhibitor: | 0.708 | CYP3A4-substrate: | 0.812 |
Clearance (CL): | 5.851 | Half-life (T1/2): | 0.225 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.127 |
Drug-inuced Liver Injury (DILI): | 0.932 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 1 | Maximum Recommended Daily Dose: | 0.09 |
Skin Sensitization: | 0.069 | Carcinogencity: | 0.464 |
Eye Corrosion: | 0.647 | Eye Irritation: | 0.09 |
Respiratory Toxicity: | 0.954 |